Evaluation of CD30 expression on T cells during the generation of EBV-CTLs and on CD30CAR+ EBV-CTLs
| . | Stimulation . | |||
|---|---|---|---|---|
| First . | Second . | Third . | Fourth or more . | |
| CD3+ T cells/EBV-CTLs | 14 ± 8 | 5 ± 4 | 6 ± 6 | 3 ± 5 |
| CD30CAR+ EBV-CTLs | 3.7 ± 1.8 | 7.2 ± 5.5 | 7.3 ± 4.5 | 1.8 ± 0.4 |
| . | Stimulation . | |||
|---|---|---|---|---|
| First . | Second . | Third . | Fourth or more . | |
| CD3+ T cells/EBV-CTLs | 14 ± 8 | 5 ± 4 | 6 ± 6 | 3 ± 5 |
| CD30CAR+ EBV-CTLs | 3.7 ± 1.8 | 7.2 ± 5.5 | 7.3 ± 4.5 | 1.8 ± 0.4 |
Data are percentages of T cells. Evaluation of CD30 expression on CD3+ T cells/CTLs and on CD30CAR+ CTLs 5 to 7 days after the indicated stimulation with autologous LCLs. Analysis was performed by FACS after staining with CD30 PE-labeled MAb. CD30 expression on circulating T cells is less than 1%.